特瑞普利单抗新辅助与辅助治疗局部区域晚期鼻咽癌:一项随机、单中心、双盲、安慰剂对照的2期试验
该随机、单中心、双盲、安慰剂对照2期试验纳入150例高危III-IVa期局部区域晚期鼻咽癌患者,比较特瑞普利单抗新辅助+辅助联合同步放化疗与安慰剂联合同步放化疗。特瑞普利单抗组2年无进展生存率为92.0%,安慰剂组为74.0%(分层HR 0.40,95%CI 0.18-0.89;P=0.019),提示该「三明治」方案具有前景。
要点
- 特瑞普利单抗组2年无进展生存率92.0%,安慰剂组74.0%(分层HR 0.40,95%CI 0.18-0.89;P=0.019)。
- 特瑞普利单抗组仅10%患者发生≥3级免疫相关不良事件。
- 最常见≥3级急性不良事件为白细胞减少(特瑞普利单抗组40% vs 安慰剂组44%)。
核心结论
- 研究提示,特瑞普利单抗新辅助+辅助联合同步放化疗的「三明治」方案可能是治疗局部区域晚期鼻咽癌极具前景的疗法。
- 作者认为需要开展3期非劣效试验,比较特瑞普利单抗新辅助+辅助治疗与顺铂+吉西他滨新辅助化疗联合同步放化疗。
研究设计与样本
- 随机、单中心、双盲、安慰剂对照2期试验,在中国广州中山大学肿瘤防治中心开展。
- 纳入年龄18-65岁、新诊断高危III-IVa期局部区域晚期鼻咽癌、治疗前血浆EBV DNA≥1500拷贝/mL、ECOG评分0-1分的成人患者。
- 患者按2:1随机分配至特瑞普利单抗组(n=100)或安慰剂组(n=50),按TNM分期(III vs IVa)分层。
- 特瑞普利单抗240 mg静脉给药每2周一次共2周期新辅助治疗,同步放化疗期间第1、22、43天顺铂100 mg/m2静脉给药,辅助特瑞普利单抗240 mg静脉给药每3周一次最多8周期;安慰剂组对应给予安慰剂。
- 主要终点为意向治疗人群的2年无进展生存率;研究注册号NCT03925090,已停止入组,随访进行中。
主要发现
- 2019年12月6日至2021年12月9日共入组150例患者,特瑞普利单抗组100例,安慰剂组50例;男性115例(77%),女性35例(23%)。
- 截至2024年5月31日数据截止,意向治疗人群无进展生存中位随访37.8个月(IQR 34.2-46.5)。
- 特瑞普利单抗组2年无进展生存率92.0%(95%CI 86.7-97.3),安慰剂组74.0%(95%CI 61.8-86.2),分层HR 0.40(95%CI 0.18-0.89),log-rank P=0.019。
- 随机化1年内最常见≥3级急性不良事件:白细胞减少(特瑞普利单抗组99例中40例[40%] vs 安慰剂组50例中22例[44%])、黏膜炎(28例[28%] vs 10例[20%])、中性粒细胞减少(17例[17%] vs 9例[18%])、贫血(16例[16%] vs 5例[10%])、体重下降(12例[12%] vs 6例[12%])。
- 随机化1年后最常见≥3级晚期不良事件为听觉或听力丧失(特瑞普利单抗组8例[8%] vs 安慰剂组4例[8%]);≥3级免疫相关不良事件仅特瑞普利单抗组发生10例(10%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with locoregionally advanced nasopharyngeal carcinoma with a high pretreatment plasma concentration of Epstein-Barr virus (EBV) DNA remain at high risk for recurrence after concurrent chemoradiotherapy. This study aimed to compare the efficacy and safety of neoadjuvant-adjuvant treatment with the PD-1 inhibitor toripalimab and concurrent chemoradiotherapy versus placebo and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. METHODS: This randomised, single-centre, double-blind, placebo-controlled, phase 2 trial was conducted at Sun Yat-sen University Cancer Centre in Guangzhou, China. Adult patients (aged 18-65 years) with newly diagnosed high-risk stage III-IVa locoregionally advanced nasopharyngeal carcinoma, with a pretreatment plasma EBV DNA concentration of at least 1500 copies per mL and an Eastern Cooperative Oncology Group performance score of 0-1, were eligible. Patients were randomly assigned (2:1) using an interactive web response system (block size of six), stratified by TNM stage (III vs IVa), to neoadjuvant toripalimab (240 mg intravenously) or placebo once every 2 weeks for two cycles, followed by concurrent cisplatin (100 mg/m2 intravenously) on days 1, 22, and 43 during intensity-modulated radiotherapy and adjuvant toripalimab (240 mg intravenously) or placebo once every 3 weeks for up to eight cycles. The primary endpoint was 2-year progression-free survival in the intention-to-treat population. This study was registered with ClinicalTrials.gov, NCT03925090, and is closed to enrolment; follow-up is ongoing. FINDINGS: Between Dec 6, 2019, and Dec 9, 2021, 150 patients were enrolled and randomly assigned to the toripalimab group (n=100) or placebo group (n=50). 115 (77%) patients were male and 35 (23%) were female. As of data cutoff (May 31, 2024), median follow-up for progression-free survival was 37·8 months (IQR 34·2-46·5) for the intention-to-treat population analyses. 2-year progression-free survival was higher in the toripalimab group (92·0% [95% CI 86·7-97·3]) than in the placebo group (74·0% [61·8-86·2]; stratified hazard ratio 0·40 [95% CI 0·18-0·89]; log-rank p=0·019). The most common grade 3 or worse acute adverse events (occurring within 1 year of randomisation) were leukopenia (40 [40%] of 99 patients in the toripalimab group vs 22 [44%] of 50 patients in the placebo group), mucositis (28 [28%] vs ten [20%]), neutropenia (17 [17%] vs nine [18%]), anaemia (16 [16%] vs five [10%]), and weight loss (12 [12%] vs six [12%]). The most common grade 3 or worse late adverse events (occurring >1 year after randomisation) was auditory or hearing loss (eight [8%] vs four [8%]). Immune-mediated adverse events of grade 3 or worse occurred in ten (10%) patients only in the toripalimab group. One (2%) of 50 patients in the placebo group died due to septic shock caused by bacteraemia considered not treatment related. There were no treatment-related deaths in the toripalimab group. INTERPRETATION: Our findings suggested that a so-called sandwich approach involving toripalimab (in the neoadjuvant and adjuvant phases) combined with concurrent chemoradiotherapy could be a highly promising therapy for the treatment of locoregionally advanced nasopharyngeal carcinoma. Phase 3 non-inferiority trials are warranted comparing neoadjuvant and adjuvant toripalimab versus cisplatin plus gemcitabine neoadjuvant chemotherapy combined with concurrent chemoradiotherapy. FUNDING: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Science and Technology Program of Guangzhou, Sun Yat-sen University Clinical Research 5010 Program, Innovative Research Team of High-level Local Universities in Shanghai, Postdoctoral Innovative Talent Support Program, Planned Science and Technology Project of Guangdong Province, Key Youth Teacher Cultivating Program of Sun Yat-sen University, and Fundamental Research Funds for the Central Universities. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Liu SL, Li XY, Yang JH, et al. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2024. PMID: 39522541. doi:10.1016/S1470-2045(24)00504-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。